Coronary Stents Market: as drug-eluting stents hold 88% revenue share on consistent clinical evidence, bioabsorbable polymer coatings and ultra-thin strut designs are compounding incremental procedural preference in complex lesion subsets, so premium DES revenue per procedure keeps rising even as government price controls compress average selling price in the highest-volume emerging markets.

The global coronary stents market size was USD 8.14 Billion in 2025 and is expected to register a revenue CAGR of 6.7% during the forecast period.Market revenue growth is driven by factors such as continuous drug-eluting stent platform innovation, expanding PCI procedural volumes in Asia Pacific, and the rising global burden of coronary artery disease.The first driving factor is continuous DES platform innovation through bioabsorbable polymer coatings and ultra-thin strut designs that extend clinical evidence differentiation in complex lesion subsets.The drug-eluting stent segment commands approximately 88% of 2025 market revenue, driven by consistent clinical evidence demonstrating materially lower target lesion revascularisation rates than bare-metal stents across the full spectrum of lesion complexity.The second driving factor is expanding PCI procedural volumes in Asia Pacific, driven by rising coronary artery disease incidence and improving cardiac catheterisation laboratory infrastructure.China's National Heart, Lung, and Blood Disease Center reported PCI procedure volume reached approximately 1.2 million procedures in 2023, a 9.4% year-on-year increase.The third driving factor is the rising global burden of coronary artery disease, with approximately 244 million cases estimated worldwide in 2024 and the WHO reporting cardiovascular disease as the leading cause of death globally at approximately 17.9 million annual deaths.Abbott reported its XIENCE family as the world's most-implanted coronary stent platform in its FY2024 Annual Report, with coronary stent revenue estimated at approximately USD 2.0 to USD 2.2 Billion.These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single DES platform widens its addressable revenue every time it adds a new clinical indication on the same underlying stent design, without the manufacturer having to develop and validate an entirely new device.Once a DES platform earns its core coronary artery disease indication, each additional indication such as bifurcation lesion treatment or high bleeding risk short-duration dual antiplatelet therapy adds incremental procedural volume on the same manufactured device, so platform revenue compounds as the indication list grows around the original approval.As a result, demand and revenue share are concentrating around DES platforms with the broadest indication set covering complex lesion subtypes and bleeding-risk populations, that hold the deepest real-world registry evidence, and the forecast tilts toward these multi-indication platforms rather than single-indication legacy devices.For instance, in March 2025, Terumo, Japan, received expanded EU MDR approval for its Ultimaster Nagomi and Ultimaster Tansei sirolimus-eluting stent systems covering patients at high bleeding risk eligible for dual antiplatelet therapy as short as one month, widening the same underlying platform's addressable patient population, which the company estimates at approximately 45% of all PCI patients, without a new device submission.These are some of the key factors driving revenue growth of the market.

Because the ORBITA-2 trial published in the New England Journal of Medicine in January 2024 demonstrated that PCI did not significantly relieve angina symptoms compared to placebo in patients without documented ischaemia, clinical practice standards for elective DES placement at community hospitals have tightened.

Government price controls are a second constraint, since India's National Pharmaceutical Pricing Authority caps DES prices at approximately INR 27,890 per unit for government procurement and China's volume-based procurement reduced DES prices to RMB 700 to RMB 800 per unit from pre-tender prices of RMB 10,000 to RMB 15,000, suppressing average selling price realisation at the global portfolio level.

Bioresorbable scaffold caution is a third constraint, because the early clinical failure documented in the ABSORB III five-year follow-up data has significantly slowed commercial acceptance of first-generation bioresorbable technology in the United States and European markets.

These factors substantially limit coronary stents market growth over the forecast period.

The clearest driver of demand is the continuous refinement of drug-eluting stent platforms through bioabsorbable polymer coatings and ultra-thin strut metallurgy. A bioabsorbable polymer coating only changes prescribing behaviour if it demonstrably shortens the required dual antiplatelet therapy duration without compromising safety, and the EVOLVE SHORT DAPT trial demonstrated exactly that for Boston Scientific's Synergy platform, so bioabsorbable-coated DES are displacing permanent-polymer designs in bleeding-risk populations specifically because of this evidence. Ultra-thin strut designs in cobalt-chromium and platinum-chromium alloy DES platforms have achieved strut thicknesses below 60 microns, compared to 80 to 130 microns in earlier-generation DES, with the TALENT trial and BIOFLOW V study demonstrating lower target lesion failure rates at 12-month follow-up. In March 2025, Terumo received expanded EU MDR approval for its Ultimaster Nagomi and Ultimaster Tansei platforms covering high bleeding risk patients eligible for one-month dual antiplatelet therapy, and the ACC/AHA 2023 Coronary Artery Revascularisation Guideline maintains a Class I recommendation for DES over BMS across all PCI indications. The effect on the market is that procedural preference is shifting toward the smaller set of DES platforms with bioabsorbable coating and ultra-thin strut evidence, concentrating revenue behind the vendors with the deepest clinical trial investment. These are some of the key factors driving revenue growth of the market.

The second driver is the structural expansion of PCI procedural capacity across China, India, and Japan. PCI volume growth only converts into stent revenue at scale if government insurance schemes extend coverage alongside capacity expansion, and India's Pradhan Mantri Jan Arogya Yojana framework has done exactly that by extending DES access to empanelled hospitals at NPPA-negotiated prices, so unit volume growth in India is now running well ahead of hospital infrastructure alone would predict. China's PCI procedure volume reached approximately 1.2 million procedures in 2023, a 9.4% year-on-year increase, while India's Cardiological Society of India estimated PCI volume at accredited centres reached approximately 520,000 to 550,000 procedures in 2024. MicroPort reported cumulative global Firesorb bioresorbable scaffold implantations exceeding one million units by September 2025, and China's NMPA granted the company a second Firesorb-related approval during the 2024 to 2025 period, extending its next-generation bioresorbable platform's addressable indication set. The effect on the market is that Asia Pacific unit volume is growing faster than any other region even as government procurement price controls hold average selling price well below developed-market levels. These are some of the key factors driving revenue growth of the market.

“MicroPort's Firesorb bioresorbable scaffold surpassed one million cumulative global implantations by September 2025, the clearest evidence yet that next-generation bioresorbable technology has moved past the ABSORB III-era commercial hesitation.”

However, the coronary stents market faces severe adoption constraints from the shift toward optimal medical therapy, government price controls, and continued bioresorbable scaffold caution.

Because the ORBITA-2 trial published in the New England Journal of Medicine in January 2024 found that PCI did not significantly reduce angina symptoms compared to placebo in patients without documented ischaemia, this reinforces ACC/AHA guidance restricting Class I PCI recommendations to patients with haemodynamically significant ischaemia, tightening the elective DES placement pipeline at community hospitals.

Government price controls compound this, since India's NPPA price cap of approximately INR 27,890 per DES unit and China's NHSA volume-based procurement pricing of RMB 700 to RMB 800 per unit, compared to US list prices of approximately USD 900 to USD 1,400 per DES, continue to suppress global average selling price uplift from Asia Pacific volume growth.

Bioresorbable scaffold caution is the third constraint, since the early clinical failure documented in the ABSORB III five-year follow-up data has significantly slowed commercial acceptance of first-generation bioresorbable technology in the United States and European markets, even as next-generation platforms accumulate more favourable evidence.

These factors substantially limit coronary stents market growth over the forecast period.

Based on stent type, the global coronary stents market is segmented into drug-eluting stents, bare-metal stents, bioresorbable vascular scaffolds, and covered coronary stents. Drug-eluting stents account for the largest revenue share at approximately 88% of 2025 market revenue. The major DES platforms include Abbott XIENCE Sierra, Boston Scientific Synergy XD and PROMUS, Medtronic Resolute Onyx, Biotronik Orsiro Mission, and Terumo Ultimaster Nagomi, reducing restenosis rates to below 5% compared to 20 to 30% with bare-metal stents. Bioresorbable vascular scaffolds are expected to register a revenue growth rate over the forecast period, supported by next-generation designs from MicroPort Firesorb and Elixir Medical DESolve that have addressed the scaffold-to-artery ratio mismatch and thrombosis risk that contributed to the ABSORB III failure rate.

Based on material, the global coronary stents market is segmented into cobalt-chromium alloy, platinum-chromium alloy, and stainless steel. Cobalt-chromium alloy accounts for the largest revenue share, used in the XIENCE, Resolute Onyx, and Orsiro Mission platforms. Platinum-chromium alloy, the material platform for Boston Scientific's Synergy XD and PROMUS products, offers improved radiopacity and enables the ultra-thin 74-micron strut profile of Synergy, making it the fastest-growing alloy sub-segment. Stainless steel is confined to legacy bare-metal stent products and early-generation DES in price-sensitive procurement environments in sub-Saharan Africa and lower-income Asia Pacific markets.

Based on regional analysis, the coronary stents market in North America accounted for the largest revenue share in 2025. The United States drives the regional position through approximately 650,000 to 700,000 annual PCI procedures and the highest average DES selling prices globally, reflecting innovation-driven premium pricing that US hospital group purchasing organisation contracts support. In October 2025, Boston Scientific's Agent Drug-Coated Balloon secured a new Medicare Technology Add-on Payment for coronary in-stent restenosis treatment, reinforcing the region's role as the primary commercial arena for premium PCI adjunct technology. The concentration of FDA clearances and premium DES launches in the United States also means new platforms are often launched in the United States first.

The market in Europe is expected to register a steady revenue growth rate in the global coronary stents market over the forecast period.

Germany, France, Italy, the United Kingdom, and Spain represent the five largest national coronary stent markets within Europe. Biotronik maintains a stronger European market position through the Orsiro Mission cobalt-chromium DES used extensively at German and Swiss cardiac centres, supported by the BIOFLOW clinical programme evidence base, while the EU MDR transition for coronary stents was completed in May 2024. Iran-US sanctions and their indirect effect on Strait of Hormuz shipping have raised costs for cobalt, chromium, and specialty polymer inputs used in European stent manufacturing, a disruption that has run through 2026 and keeps manufacturing input costs above pre-2022 baseline levels.

The market in Asia Pacific is expected to register a rapid revenue growth rate in the global coronary stents market over the forecast period.

China, India, Japan, and South Korea represent the four largest national coronary stent markets within the region. China's NHSA volume-based procurement programme has accelerated domestic manufacturer share gains for MicroPort Medical, Lepu Medical, and Shandong JW Medical Systems, which collectively hold an estimated 55 to 65% of Chinese DES unit volume, while India represents the fastest unit volume growth market with PCI procedure volume expanding at an estimated 8 to 10% annually. Japan's PCI procedural volume of approximately 280,000 annual procedures is supported by the national health insurance reimbursement framework, with Terumo's Ultimaster platform maintaining a leading domestic position, leaving more structural room for premium platform growth than in the already price-controlled Chinese market.

The market in Latin America is expected to register a moderate revenue growth rate in the global coronary stents market over the forecast period.

Brazil and Mexico represent the two largest national coronary stent markets within the region, with Brazil's ANVISA classifying coronary stents as Class III medical devices requiring registration and clinical data. Iran-US sanctions and their indirect effect on Strait of Hormuz shipping have maintained elevated import costs for specialty metals and polymer components entering Brazilian and Mexican distribution networks, a disruption that has run through 2026 and constrains public-sector SUS tender pricing below private hospital sector levels.

The market in Middle East and Africa is expected to register a moderate revenue growth rate in the global coronary stents market over the forecast period.

Saudi Arabia and the United Arab Emirates represent the primary commercial markets within the GCC. Saudi Arabia is the most established market on the continent for premium DES access, supported by the Vision 2030 healthcare investment programme, while sub-Saharan Africa remains the primary market for stainless steel bare-metal stents in price-sensitive procurement environments.